Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly crawled date : 2021 - 09 - 28 save search
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE A | $25.955 0.17% 4.8M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
F-Secure Becomes Cybersecurity Awareness Month 2021 Champion
Published: 2021-09-28 (Crawled : 15:00) - prnewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
MAR | $246.0 -0.97% 260K
|
Consumer Services
|
| O: -0.77%
H: 1.42%
C: 0.3%
security cybersecurity
Care Access and Eli Lilly and Company Partner to Increase Diversity Within Oncology Clinical Trials
Published: 2021-09-28 (Crawled : 14:15) - biospace.com/
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
clinical trials trials trial
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
NVO | $123.5 -0.32% 1M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: -1.28%
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ALNY | $147.285 -0.28% 13K
|
Health Technology
|
| O: -7.01%
H: 2.22%
C: -1.77%
alcohol use disorder treatment phase 1 trial
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ford test injection insulin
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Published: 2021-09-28 (Crawled : 07:00) - prnewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
collaboration license
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
Published: 2021-09-28 (Crawled : 00:00) - prnewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
INCY | $53.85 0.79% 100K
|
Health Technology
|
| O: -0.27%
H: 0.81%
C: -0.56%
collaboration license
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
TPET | $0.4801 107.75% 16M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
SPCB | $0.4278 55.0% 17M
|
Electronic Technology
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 25M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.5155 33.52% 3.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.